Nicholas J. Laping

8.0k total citations · 2 hit papers
82 papers, 6.3k citations indexed

About

Nicholas J. Laping is a scholar working on Molecular Biology, Oncology and Physiology. According to data from OpenAlex, Nicholas J. Laping has authored 82 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Molecular Biology, 15 papers in Oncology and 14 papers in Physiology. Recurrent topics in Nicholas J. Laping's work include TGF-β signaling in diseases (15 papers), S100 Proteins and Annexins (11 papers) and Urinary Bladder and Prostate Research (9 papers). Nicholas J. Laping is often cited by papers focused on TGF-β signaling in diseases (15 papers), S100 Proteins and Annexins (11 papers) and Urinary Bladder and Prostate Research (9 papers). Nicholas J. Laping collaborates with scholars based in United States, United Kingdom and Netherlands. Nicholas J. Laping's co-authors include John D. Harling, James F. Callahan, Laramie M. Gaster, Caleb E. Finch, Nancy R. Nichols, Francisco José Nicolás, Alastair D. Reith, Gareth J. Inman, Caroline S. Hill and Jonathan Day and has published in prestigious journals such as Cancer Research, Brain Research and Clinical Cancer Research.

In The Last Decade

Nicholas J. Laping

82 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7

2002 1.4k citations Gareth J. Inman, Francisco José Nicolás et al. Molecular Pharmacology profile →
Inhibition of Transforming Growth Factor (TGF)-β1–Induced Extracellular Matrix with a Novel Inhibitor of the TGF-β Type I Receptor Kinase Activity: SB-431542

2002 544 citations Nicholas J. Laping, Eugene T. Grygielko et al. Molecular Pharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nicholas J. Laping United States	34	3.7k	988	719	597	567	82	6.3k
Alastair D. Reith United Kingdom	35	4.6k 1.2×	657 0.7×	936 1.3×	832 1.4×	382 0.7×	52	7.1k
Teresa L. Wood United States	44	2.5k 0.7×	791 0.8×	657 0.9×	404 0.7×	459 0.8×	113	5.1k
Brian Harding United Kingdom	46	2.8k 0.8×	1.0k 1.1×	909 1.3×	524 0.9×	226 0.4×	162	6.9k
Masakiyo Sasahara Japan	43	2.1k 0.6×	592 0.6×	647 0.9×	594 1.0×	489 0.9×	146	5.3k
Kiyofumi Asai Japan	36	2.2k 0.6×	760 0.8×	641 0.9×	414 0.7×	465 0.8×	160	4.2k
Neeraj Agarwal United States	40	3.6k 1.0×	508 0.5×	972 1.4×	326 0.5×	336 0.6×	118	5.2k
Katya Ravid United States	51	2.8k 0.8×	631 0.6×	332 0.5×	606 1.0×	327 0.6×	174	6.8k
Luisa Roncali Italy	36	3.1k 0.8×	1.1k 1.1×	448 0.6×	507 0.8×	765 1.3×	152	5.8k
Stefan Isenmann Germany	38	3.6k 1.0×	434 0.4×	1.3k 1.8×	364 0.6×	973 1.7×	125	6.1k
Klaus Seuwen Switzerland	41	3.9k 1.1×	709 0.7×	1.0k 1.4×	679 1.1×	167 0.3×	97	5.9k

Countries citing papers authored by Nicholas J. Laping

Since Specialization

Citations

This map shows the geographic impact of Nicholas J. Laping's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicholas J. Laping with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicholas J. Laping more than expected).

Fields of papers citing papers by Nicholas J. Laping

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicholas J. Laping. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicholas J. Laping. The network helps show where Nicholas J. Laping may publish in the future.

Co-authorship network of co-authors of Nicholas J. Laping

This figure shows the co-authorship network connecting the top 25 collaborators of Nicholas J. Laping. A scholar is included among the top collaborators of Nicholas J. Laping based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicholas J. Laping. Nicholas J. Laping is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dluzen, Dean E., Janet L. McDermott, Mélanie Bourque, et al.. (2011). Markers Associated with Sex Differences in Methamphetamine-Induced Striatal Dopamine Neurotoxicity. Current Neuropharmacology. 9(1). 40–44. 14 indexed citations

Thompson, Scott K., David G. Washburn, James S. Frazee, et al.. (2009). Rational design of orally-active, pyrrolidine-based progesterone receptor partial agonists. Bioorganic & Medicinal Chemistry Letters. 19(16). 4777–4780. 11 indexed citations

Sherk, Andrea B., Daniel E. Frigo, Christine G. Schnackenberg, et al.. (2008). Development of a Small-Molecule Serum- and Glucocorticoid-Regulated Kinase-1 Antagonist and Its Evaluation as a Prostate Cancer Therapeutic. Cancer Research. 68(18). 7475–7483. 174 indexed citations

Su, Xin, Lisa A. Leon, Charlene Wu, et al.. (2008). Modulation of bladder function by prostaglandin EP ₃ receptors in the central nervous system. American Journal of Physiology-Renal Physiology. 295(4). F984–F994. 32 indexed citations

Khandekar, Sanjay S., et al.. (2005). A Liquid Chromatography/Mass Spectrometry-Based Method for the Selection of ATP Competitive Kinase Inhibitors. SLAS DISCOVERY. 10(5). 447–455. 18 indexed citations

Barone, Frank C., Wallace G. Campbell, Allen H. Nelson, et al.. (2002). The Angiotensin Type 1 Receptor Antagonist, Eprosartan, Attenuates the Progression of Renal Disease in Spontaneously Hypertensive Stroke-Prone Rats with Accelerated Hypertension. Journal of Pharmacology and Experimental Therapeutics. 301(1). 21–28. 15 indexed citations

Inman, Gareth J., Francisco José Nicolás, James F. Callahan, et al.. (2002). SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7. Molecular Pharmacology. 62(1). 65–74. 1406 indexed citations breakdown →

Laping, Nicholas J., Barbara A. Olson, & Yuan Zhu. (2001). Identification of a Novel Nuclear Guanosine Triphosphate-Binding Protein Differentially Expressed in Renal Disease. Journal of the American Society of Nephrology. 12(5). 883–890. 17 indexed citations

Laping, Nicholas J., Allen H. Nelson, Lisa C. Contino, et al.. (2001). Renoprotective effects of carvedilol in hypertensive‐stroke prone rats may involve inhibition of TGFβ expression. British Journal of Pharmacology. 134(5). 977–984. 32 indexed citations

10.

Morgan, Todd E., Irina Rozovsky, Dipak K. Sarkar, et al.. (2000). Transforming growth factor-β1 induces transforming growth factor-β1 and transforming growth factor-β receptor messenger RNAs and reduces complement C1qB messenger RNA in rat brain microglia. Neuroscience. 101(2). 313–321. 24 indexed citations

11.

Laping, Nicholas J.. (1999). Hepatocyte growth factor in renal disease: cause or cure?. Cellular and Molecular Life Sciences. 56(5-6). 371–377. 5 indexed citations

12.

Ali, Shujath M., Nicholas J. Laping, Todd A. Fredrickson, et al.. (1998). Angiotensin-Converting Enzyme Inhibition Attenuates Proteinuria and Renal TGF-β1 mRNA Expression in Rats with Chronic Renal Disease. Pharmacology. 57(1). 20–27. 17 indexed citations

13.

Laping, Nicholas J., Barbara A. Olson, Robin DeWolf, et al.. (1998). Activation of Glomerular Mesangial Cells by Hepatocyte Growth Factor Through Tyrosine Kinase and Protein Kinase C. Biochemical Pharmacology. 55(2). 227–234. 10 indexed citations

14.

Johnson, Steve A., et al.. (1996). Perforant Path Transection Induces Complement C9 Deposition in Hippocampus. Experimental Neurology. 138(2). 198–205. 29 indexed citations

15.

Laping, Nicholas J., Bruce Teter, Nancy R. Nichols, Irina Rozovsky, & Caleb E. Finch. (1994). Glial Fibrillary Acidic Protein: Regulation by Hormones, Cytokines, and Growth Factors. Brain Pathology. 4(3). 259–275. 191 indexed citations

16.

Nichols, Nancy R., Nicholas J. Laping, Jonathan Day, & Caleb E. Finch. (1991). Increases in transforming growth factor‐β mRNA in hippocampus during response to entorhinal cortex lesions in intact and adrenalectomized rats. Journal of Neuroscience Research. 28(1). 134–139. 71 indexed citations

17.

Lampert-Etchells, Martha, et al.. (1991). Sulfated glycoprotein-2 is increased in rat hippocampus following entorhinal cortex lesioning. Brain Research. 563(1-2). 101–106. 48 indexed citations

18.

Laping, Nicholas J., Dean E. Dluzen, & V.D. Ramírez. (1991). Prolactin stimulates dopamine release from the rat corpus striatum in the absence of extra-cellular calcium. Neuroscience Letters. 134(1). 1–4. 6 indexed citations

19.

Laping, Nicholas J., et al.. (1990). Aging alters opiate inhibition of potassium (K+)-stimulated dopamine release from the corpus striatum of male rats. Neurobiology of Aging. 11(4). 395–399. 12 indexed citations

20.

Dluzen, Dean E., Nicholas J. Laping, & V.D. Ramírez. (1988). The importance of striatal interneurons in age-related effects upon potassium-and amphetamine-stimulated dopamine release. Brain Research. 445(2). 354–357. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact